Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial by Davies, Christina, Dr, Pan, Hongchao, PhD, Godwin, Jon, DPhil, Gray, Richard, Prof, Arriagada, Rodrigo, Prof, Raina, Vinod, Prof, Abraham, Mirta, MD, Alencar, Victor Hugo Medeiros, MD, Badran, Atef, PhD, Bonfill, Xavier, MD, Bradbury, Joan, Clarke, Michael, Prof, Collins, Rory, Prof, Davis, Susan R, Prof, Delmestri, Antonella, PhD, Forbes, John F, Prof, Haddad, Peiman, Prof, Hou, Ming-Feng, Prof, Inbar, Moshe, Prof, Khaled, Hussein, Prof, Kielanowska, Joanna, MD, Kwan, Wing-Hong, MD, Mathew, Beela S, MD, Mittra, Indraneel, Prof, Müller, Bettina, MD, Nicolucci, Antonio, MD, Peralta, Octavio, MD, Pernas, Fany, Petruzelka, Lubos, Prof, Pienkowski, Tadeusz, Prof, Radhika, Ramachandran, MD, Rajan, Balakrishnan, MD, Rubach, Maryna T, MD, Tort, Sera, MD, Urrútia, Gerard, MD, Valentini, Miriam, MD, Wang, Yaochen, MD, Peto, Richard, Prof

Get full text